Pfizer Inc. (PFE)
Pfizer: Too Cheap To Miss Out
Pfizer's stock is currently trading below pre-pandemic levels, despite the record-breaking year it had in 2023 for FDA approvals and the significant acquisition of Seagen. Weak sentiment is likely explained by the significant risk of two best-selling products losing their exclusivity in 2026. Intrinsic value calculations suggest that the stock is 75% undervalued, meaning that the biggest risk is likely factored in.
Why Things Could Get Worse for Pfizer Stock Before They Get Better
Pfizer has been trimming expenses as it adjusts to a decline in demand related to COVID-19. It recently announced a new cost-cutting plan that will save $1.5 billion in expenses.
1 Beaten-Down S&P 500 Dividend Stock to Buy in June and Hold For a Decade or Longer
Sales of Pfizer's COVID-19-related products are down sharply, and so is the stock price. Pfizer stock has fallen about 24% over the past year.
3 Discounted Stocks Poised for a Major Upswing
Due to their robust financial and strategic approaches, these three equities are all seeing notable progress in their respective industries. Recent financial results for the first one show robust revenue growth and enhanced gross margins, underpinned by efficient cost control.
Is Pfizer the Best Dividend Stock for You?
Pfizer's COVID-19 vaccine revenue is drying up. But the company's push into oncology should reignite growth.
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
Pfizer expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 after most patients treated for a form of lung cancer had no disease progression after five years.
Pfizer (PFE) Up 1.8% Since Last Earnings Report: Can It Continue?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
Pfizer's drug for advanced lung cancer shows promising long-term trial results
Pfizer on Friday said its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial, which could help establish it as the new standard treatment for the condition. Lorbrena is already approved in the U.S. for treating adults with advanced non-small cell lung cancer who have a mutation in a gene called ALK.
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
Pfizer said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the strength of data presented on Friday showing most patients treated for a rare form of advanced lung cancer in a clinical trial were alive without the disease worsening after five years.
EU regulator recommends use of Pfizer's gene therapy for rare bleeding disorder
The European Medicines Agency has recommended the use of Pfizer's gene therapy for a rare bleeding disorder called hemophilia B, which typically requires regular infusions of a blood-clotting protein, the regulator said on Friday.
Is Pfizer an Excellent Dividend Stock to Buy for Passive Income Investors?
Pfizer's dividend yield is rising as the stock price is falling.
Healthy Returns: Pfizer, Merck, J&J and more to release cancer drug data at industry conference
CNBC will be on the ground at the ASCO annual meeting in Chicago. Meanwhile, Epic released a free tool set to help health systems evaluate AI models.
